Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma

Next Previous
X
Search
Trial Profile

Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GD2-SADA (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Malignant melanoma; Sarcoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms SADA Y-PRIT
  • Sponsors Y-mAbs Therapeutics

    • Most Recent Events

    • 06 Sep 2024 According to a Y-mAbs Therapeutics Media Release, data from the study will be presented at the American Academy of Cancer Research (AACR) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada.
    • 12 Aug 2024 According to a Y-mAbs Therapeutics media release, Part A of this study expected to be completed in the fourth quarter of 2024.
    • 11 Apr 2024 Planned End Date changed from 1 Jan 2025 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top